Dr. Formenti on Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy in TNBC

Silvia Formenti, MD
Published: Thursday, May 29, 2014

Silvia Formenti, MD, The Sandra and Edward H. Meyer Professor of Radiation Oncology chair, Radiation Oncology, NYU Langone Medical Center, associate director, Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses a trial that examines concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer (TNBC).

Formenti says research has shown that women who have a robust immunological response against their own tumor are more likely to be alive in 5-10 years. In this ongoing study, researchers decided to combine carboplatin and radiation based on preclinical work that showed that the combination can induce an immunogenic cell death. This type of cell death, Formenti says, also elicits a response from the immune system.

So far, the study has accrued 38 patients and the regimen is very well tolerated, Formenti says. At the median follow-up, which was slightly greater than 2 years, only one patient has recurred.

<<< View more from the 2014 ASCO Annual Meeting

Silvia Formenti, MD, The Sandra and Edward H. Meyer Professor of Radiation Oncology chair, Radiation Oncology, NYU Langone Medical Center, associate director, Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses a trial that examines concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer (TNBC).

Formenti says research has shown that women who have a robust immunological response against their own tumor are more likely to be alive in 5-10 years. In this ongoing study, researchers decided to combine carboplatin and radiation based on preclinical work that showed that the combination can induce an immunogenic cell death. This type of cell death, Formenti says, also elicits a response from the immune system.

So far, the study has accrued 38 patients and the regimen is very well tolerated, Formenti says. At the median follow-up, which was slightly greater than 2 years, only one patient has recurred.

<<< View more from the 2014 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x